Pharmesis International Ltd (BFK) Fair Value & Analysis
Healthcare · SG · Market cap 13.2M SGD
Fair value as of: Jul 4, 2026
From 7 valuation models · updated today
Share price +15.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.2150 SGD – 0.4746 SGD · fair‑value band 0.1500 SGD – 0.2800 SGD · the 0.4150 SGD price screens above the 0.2000 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pharmesis International Ltd (BFK) currently trades at 0.4150 SGD, while our model-based Fair Value estimate is 0.2000 SGD — implying the stock looks roughly 51.8% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Pharmesis International Ltd generated revenue of 43.8M SGD at a net margin of -9.8%. Revenue declined 62.2% year over year. It earns a return on equity of -7.4%. Net debt stands at 10.7M SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution. It provides prescribed products and over-the-counter drugs. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment. It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharmesis International Ltd reported revenue of 43.8M SGD in FY2025 versus 52.8M SGD in FY2021, a compound −4.6%/yr. Reported net income was −4.3M SGD in FY2025.
Is BFK fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharmesis International Ltd (BFK) undervalued?
What is the fair value of BFK?
What is the quality score of BFK?
What is the revenue of Pharmesis International Ltd (BFK)?
What is the net profit margin of BFK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.